OraSure Technologies Announces Public Offering

OraSure Technologies Announces Public Offering

Business Wire - September 10, 2003

BETHLEHEM, Pa.--OraSure Technologies, Inc., the market leader in oral fluid diagnostics, today announced that it plans to publicly offer 5,000,000 shares of its common stock. The offering will be made pursuant to a registration statement covering shares of common stock that became effective on August 8, 2003. The Company will grant to the underwriters an option to purchase an additional 750,000 shares of its common stock not later than 30 days after the offering to cover over-allotments incurred in the offering. Thomas Weisel Partners LLC will be the lead underwriter and SG Cowen Securities Corporation and Wells Fargo Securities, LLC will be co-managers of the offering.

OraSure intends to use the net proceeds from the offering for general working capital, commercialization of new products, research and development activities, potential acquisitions, capital expenditures, patent license fees, debt service and retirement, and general corporate purposes.

OraSure Technologies develops, manufactures and markets oral fluid specimen collection devices and tests and other diagnostic products using its proprietary technologies, including immunoassays and other in vitro diagnostic tests and other medical devices. These products are sold in the United States and certain foreign countries to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, government agencies, physicians' offices, and commercial and industrial entities. For more information on the Company, please visit www.orasure.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. A shelf registration statement relating to the shares that the Company intends to sell has previously been filed with, and declared effective by, the Securities and Exchange Commission. Any offer, if at all, will be made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A copy of the prospectus supplement related to the offering can be obtained when available from Thomas Weisel Partners LLC Investment Banking at 390 Park Avenue, New York, NY 10022.

CONTACT: OraSure Technologies, Inc.

Ronald H. Spair, 610-882-1820

Investorinfo@orasure.com

SOURCE: OraSure Technologies, Inc.

030910
BW030909

Copyright © 2003 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, iMetrikus, Inc., John M. Lloyd Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2003. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2003. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .